Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines the potential of alpha-ketoglutaric acid as an anti-aging agent and for treating age-related diseases, emphasizing its metabolic, immune, and cosmetic benefits but reports no new clinical trials.

This study found that glibenclamide exhibited a cytostatic effect on MDA-MB-231 breast cancer cells, potentially mediated through K ATP channels, and enhanced the antiproliferative impact of doxorubicin.

This study found that dihydrotestosterone (DHT) suppresses prostaglandin E2 and TGF-β induced IGF-I gene promoter activity in osteoblasts, suggesting complex interactions among bone growth regulators and potential complications from anabolic steroid use.

This study found that taurine significantly mitigated DHT-induced androgenetic alopecia in male C57BL/6 mice by promoting hair regrowth, enhancing hair follicle cycle progression, reducing apoptosis, and downregulating key androgen-related signaling pathways, highlighting its potential as a therapeutic candidate for hair loss management.

AGA treated with finasteride, minoxidil, and hair transplantation.

This study found that circAGK was highly expressed in AGA patients and promoted dermal papilla cell apoptosis, suggesting it as a potential target for treating androgen alopecia.

This study found that prostaglandin D2 increases testosterone production in human keratinocytes through a mechanism involving ROS and REDOX potential, which could inform treatments for androgenic alopecia.

This study identified CXXC5 as a key mediator of hair loss induced by PGD2 and DHT via suppression of the Wnt/β-catenin pathway, with implications for potential therapeutic targets.

In this study, Terminalia bellirica extracts promoted hair regrowth in testosterone-induced AGA mice, possibly by inhibiting type II 5α-reductase activity and enhancing the MAPK signaling pathway.

This review discusses androgenetic alopecia and existing treatments, reporting no new clinical results; the authors highlight promising prospects for androgen receptor degrader drugs among therapeutic options.

Adding a cosmetic gel with caffeine, taurine, and growth factors to standard hair loss treatments could improve results.

This study identified 30 new compounds with significant androgen receptor binding affinity through a combination of virtual screening and in vitro testing.

This study found that compounds from *Tectona grandis* leaves showed moderate inhibition of steroid 5α-reductase, a factor in androgenetic alopecia, and exhibited anti-inflammatory properties by inhibiting nitric oxide and pro-inflammatory cytokines IL-1β and IL-6 in vitro, suggesting potential dual-action benefits for AGA management.

This study found that dutasteride 0.5 mg was generally well-tolerated and led to overall improvement in male patients aged 18 to 41 with androgenic alopecia in a Korean clinical practice setting.

This randomized trial found that topical GT20029 significantly increased hair counts and width in Chinese men with androgenetic alopecia over 12 weeks, showing better results than placebo, with the 0.5% once daily and 1.0% twice weekly doses particularly effective.

In this study, researchers developed a method to automatically detect androgen receptor nuclear translocation in dermal papilla cells using fluorescence markers and image analysis, finding that the receptor's nuclear signal peaks about 20 minutes after DHT exposure.

This study suggests that Gambogic Amide may act as an anti-hair greying and hair growth-promoting molecule in human hair follicles in vitro by maintaining pigmentation and stimulating hair shaft elongation.

This study reviewed existing literature and found that green tea may have potential as a treatment for male androgenetic alopecia, demonstrating hair growth stimulation and fewer adverse reactions compared to minoxidil, despite being used in smaller concentrations.

This article discusses a potential link between adipocyte-myofibroblast transition and androgenetic alopecia, suggesting AMT may play a role in fibrosis associated with the condition but presents no new results.

This study found that all-trans-retinoic acid (ATRA) inhibits mink hair follicle growth by reducing dermal papilla cell proliferation and inducing apoptosis, likely through the TGF-β2/Smad2/3 pathway.

This study found that administering adipose-derived stem cells with ATP improved hair regrowth in male mice with androgenetic alopecia, while the combination was less effective in female mice.

This study identified TGFβ-2 as a potential driver of progenitor cell loss in hair follicles from early androgenetic alopecia scalps, suggesting its role in the condition's molecular disturbances.

This study found that TPA induces apoptosis in pig renal epithelial cells by affecting cell cycle proteins, and activated ras can prevent this process.

This study found that in mouse embryonic fibroblast cells lacking autophagy function, overexpression of Atg5 increased cell proliferation, while restoring autophagy reversed this effect, highlighting Atg5's dual role in tumorigenesis depending on autophagy conditions.

This study found that thulium laser therapy significantly improved hair regrowth and patient satisfaction in individuals with androgenic alopecia, demonstrating safety and effectiveness with no reported adverse events during short-term evaluation.

This study found that the tetracycline-regulated transcription system effectively controls conditional gene expression in the mouse epidermis, allowing suppression and activation of specific genes with doxycycline.

This study found that the proprietary aptamer TAGX-0003 significantly inhibited IFNγ-induced effects in pre-clinical human models of alopecia areata, promoting hair regrowth and potentially preventing disease relapse.